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論文の要旨 
Abstract of thesis 
 
The transcription factor cyclic AMP-responsive element-binding protein H (CREBH, encoded by Creb3l3) 
is highly expressed in the liver and small intestine. Hepatic CREBH contributes to glucose and triglyceride 
metabolism by regulating Fgf21 expression. However, the intestinal CREBH function remains unknown. Thus, the 
applicant aimed to elucidate the role of intestinal CREBH in energy metabolism. 
To investigate the influence of intestinal CREBH on cholesterol metabolism, the applicant compared 
plasma, bile, fecal, and tissue cholesterol levels between wild-type (WT) mice and mice overexpressing active human 
CREBH mainly in the small intestine (CREBH Tg mice) under different dietary conditions. Tg mice were a fed 
lithogenic diet (LD) for 2 weeks. Plasma, hepatic, gallbladder, and fecal lipid levels were measured. Images of the 
gallbladders were analyzed by the polarized light microscopy for the presence of cholesterol monohydrate crystals 
and sandy stones. mRNA expressions of the genes related to lipid metabolism in the liver and intestine were examined. 
In addition, the applicant performed luciferase assay using the Caco-2 colon cells and EMSA to determine the 
CREBH target gene. 
The applicant revealed that endogenous CREBH was broadly expressed in the small intestine, but the 
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 expression was higher in jejunum than other sub-regions. CREBH-Tg mice overexpressed the active form of human 
CREBH in small intestine, colon, adipose tissues, and muscle. To explore the effects of CREBH on cholesterol 
metabolism, the applicant examined numerous metabolic indices using WT and CREBH-Tg mice fed either a normal 
chow diet or a LD for 2 weeks. There were no differences in body weight, liver weight, white adipose tissue (WAT) 
weight, and food intake between WT and CREBH-Tg mice fed either normal chow or LD. There was also no 
difference in the level of plasma cholesterol between genotypes when fed a normal chow diet. However, it is found 
that LD-fed CREBH-Tg mice show 33% lower plasma cholesterol levels compared to LD-fed WT mice. Consistent 
with this result, the applicant found that the livers of CREBH-Tg mice appeared healthier than those of WT mice 
following 2 weeks of LD, and histological analysis of liver sections showed that CREBH overexpression decreased 
lipid droplet accumulation compared to WT mice. It is found that CREBH-Tg mice have significantly lower intestinal 
cholesterol levels than WT mice as well. Conversely, CREBH-Tg mice exhibited significantly higher fecal 
cholesterol output than WT mice, while fecal bile acid output did not differ between genotypes. These results indicate 
that CREBH overexpression reduces dietary cholesterol absorption in the intestine, resulting in lower liver and 
plasma cholesterol levels and higher fecal excretion.   
Based on these findings that CREBH overexpression prevents LD-induced hypercholesterolemia and 
cholelithiasis, the applicant examined the mRNA expression levels of lipid metabolism-related genes in intestine to 
identify a gene(s) regulated by CREBH. The applicant found that intestinal cholesterol transporters expression 
including Npc1l1, Abca1, Srb1, Abcg5/8 decreased in LD-fed CREBH Tg mice compared to that in LD-fed WT mice. 
It is known that NPC1L1 is a rate-limiting transporter mediating intestinal cholesterol absorption. Thus, to reveal the 
molecular mechanism how CREBH prevents systemic hypercholesterolemia, the applicant examined the effects of 
CREBH on Npc1l1 promoter activity in Caco-2 colon cancer cell line using a series of mouse Npc1l1 promoter-
luciferase constructs. It is found that the Npc1l11 promoter activity is reduced by overexpression of CREBH in a 
dose-dependent manner. EMSA assay indicated that HA-CREBH binds to Npc1l1 promoter region -32 bp to +5 bp. 
These data indicate that CREBH directly regulates Npc1l1 expression. 
Taken together, it is likely that CREBH controls the cholesterol uptake in intestine through the 
transcriptional regulation of Npc1l1 gene. 
 
 
審査の要旨 
 Abstract of assessment result 
【批評 Review】 
This study found that intestinal CREBH functions as a metabolic regulator to attenuate diet-induced 
hypercholesterolemia and cholelithiasis by decreasing expression of the transporter gene Npc1l1. It is known that 
hepatic CREBH has the potential to ameliorate hypertriglyceridelemia. This study identifies intestinal CREBH as 
another possible therapeutic target for the treatment of hypercholesterolemia and related metabolic diseases. Thus, it 
is highly expected that drugs controlling CREBH activity throughout the intestinal−hepatic system could be 
efficacious treatments for metabolic diseases and surely have impact in this field. 
 
 
 【最終試験の結果 Result】 
The final examination committee conducted a meeting as a final examination on 19th Jan, 2017. The 
applicant provided an overview of dissertation, addressed questions and comments raised during Q&A session. All 
of the committee members reached a final decision that the applicant has passed the final examination. 
 
【結論 Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be awarded Doctor 
of Philosophy in Human Biology. 
 
 
 
 
